Literature DB >> 2227543

Radical wide excision and selective inguinal node dissection for squamous cell carcinoma of the vulva.

T W Burke1, C A Stringer, D M Gershenson, C L Edwards, M Morris, J T Wharton.   

Abstract

Limited resection of some vulvar cancers may provide cure rates equivalent to those obtained with radical vulvectomy and bilateral inguinal node dissection. Rapid recovery, fewer complications, and better functional result have been described as advantages to less extensive procedures. Since 1978, 32 patients with invasive squamous cell cancer of the vulva (depth greater than 1 mm) and clinically negative inguinal lymph nodes underwent radical wide excisions as primary therapy. Mean age at diagnosis was 61 years. Seventeen patients had T1 and 15 had T2 tumors. Resection of the primary lesion was tailored to lesion location and size, and dissection was carried to the deep perineal fascia. Twenty-two patients had unilateral superficial inguinal lymph node dissections, five with midline lesions had bilateral superficial dissections, and five had node samplings which included deep inguinal nodes. Depth of invasion ranged from 1.5 to 13.0 mm. Mean largest lesion dimension was 23 mm. Five-year lifetable survival for the entire group was 84%. Univariate analysis of potential prognostic variables showed no significant recurrence or survival differences for patient age (P = 0.56), symptom duration (P = 0.57), FIGO stage (P = 0.67), tumor grade (P = 0.20), tumor location (P = 0.26), depth of invasion (P = 0.56), or resection margin status (P = 0.63). Thirty-one percent of patients had perioperative complications, and 16% developed delayed complications. Mean hospital stay was 10 days. Three patients (10%) developed new or recurrent vulvar disease and underwent additional therapy. None have died of disease, although one is alive with persistent tumor. Radical wide excision and selective inguinal lymphadenectomy constitute a reasonable alternative to radical vulvectomy with bilateral inguinal node dissections for squamous tumors clinically limited to the vulva. Outcome may not be strongly influenced by lesion size or depth of invasion.

Entities:  

Mesh:

Year:  1990        PMID: 2227543     DOI: 10.1016/0090-8258(90)90067-u

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  5 in total

Review 1.  Contemporary quality of life issues affecting gynecologic cancer survivors.

Authors:  Jeanne Carter; Richard Penson; Richard Barakat; Lari Wenzel
Journal:  Hematol Oncol Clin North Am       Date:  2011-12-16       Impact factor: 3.722

2.  Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose.

Authors:  Karishma Khullar; Tomas Patrich; Salma K Jabbour; Lara Hathout
Journal:  Appl Radiat Oncol       Date:  2022-03

3.  Is bilateral lymphadenectomy for midline squamous carcinoma of the vulva always necessary? An analysis from Gynecologic Oncology Group (GOG) 173.

Authors:  Robert L Coleman; Shamshad Ali; Charles F Levenback; Michael A Gold; Jeffrey M Fowler; Patricia L Judson; Maria C Bell; Koen De Geest; Nick M Spirtos; Ronald K Potkul; Mario M Leitao; Jamie N Bakkum-Gamez; Emma C Rossi; Samuel S Lentz; James J Burke; Linda Van Le; Cornelia L Trimble
Journal:  Gynecol Oncol       Date:  2012-11-29       Impact factor: 5.482

Review 4.  Emotional and sexual concerns in women undergoing pelvic surgery and associated treatment for gynecologic cancer.

Authors:  Cara Stabile; Abigail Gunn; Yukio Sonoda; Jeanne Carter
Journal:  Transl Androl Urol       Date:  2015-04

5.  Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer.

Authors:  Toshiaki Saito; Tsutomu Tabata; Hitoshi Ikushima; Hiroyuki Yanai; Hironori Tashiro; Hitoshi Niikura; Takeo Minaguchi; Toshinari Muramatsu; Tsukasa Baba; Wataru Yamagami; Kazuya Ariyoshi; Kimio Ushijima; Mikio Mikami; Satoru Nagase; Masanori Kaneuchi; Nobuo Yaegashi; Yasuhiro Udagawa; Hidetaka Katabuchi
Journal:  Int J Clin Oncol       Date:  2017-11-20       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.